Perseus Proteomics News

Perseus Proteomics: Announcement of the agreement on joint research on multi-specific antibodies with Yamagata University, Osaka City University, and the University of Tokyo.

Aug 2 14:05

Perseus Proteomics: Announcements of individual stocks: Yamagata University, Osaka City University, and Tokyo University of Agriculture and Technology have signed a joint research agreement on multi-specific antibodies.

Aug 2 14:05

Perseus Proteomics: Regarding inquiries about IR, please contact us by phone.

Aug 1 15:00

Perseus Proteomics: Change Report (Stock Certificates Eligible for Special Provisions, etc.)

Jul 22 14:44

Perseus Proteomics: Announcements of individual stocks: Approval of PPMX-T002 research presentation at the EANM'24 annual meeting.

Jul 19 15:30

Perseus Proteomics: Announcements of individual stocks: The presentation of the research results of the PPMX-T002 at the EANM (European Association of Nuclear Medicine) 24th Annual Meeting has been accepted.

Jul 19 15:30

Perseus Proteomics: Announcements of individual stocks for the presentation of interim report on PPMX-T003 Phase I at the 14th Japan International Health Symposium in 2024.

Jul 16 12:00

Perseus Proteomics: At the 14th JSH International Symposium in 2024, an interim report on the clinical trial of PPMX-T003 was presented.

Jul 16 12:00

Perseus Proteomics: Change report (exemption share certificates, etc.)

Jul 5 14:34

Perseus Proteomics: Change report (exemption share certificates, etc.)

Jul 4 14:53

Perseus Proteomics: Announcements of individual stocks regarding the large exercise, completion of exercise, and monthly exercise status of the 28th subscription rights (with exercise price adjustment clause) through third-party allocation.

Jul 1 15:05

Perseus Proteomics: Announcements of individual stocks regarding monthly exercise status of 28th subscription rights (with exercise price adjustment clause) by third party allotment.

Jul 1 14:05

Perseus Proteomics: Announcements of individual stocks: Notice regarding the completion of Phase I clinical trial for genuine polycythemia vera (PV) - PPMX-T003

Jun 28 14:05

Perseus Proteomics: Announcements of individual stocks: PPMX-T003: Announcement of the end of Phase I trial for polycythemia vera (PV).

Jun 28 14:05

Perseus Proteomics: Announcements of individual stocks: Publication of a paper on ANKL therapy co-authored by Osaka University and Perseus Proteomics

Jun 28 13:10

Perseus Proteomics: Announcements of individual stocks: Co-authorship paper with Osaka University on Aggressive NK cell leukemia (ANKL), PPMX-T003.

Jun 28 13:10

Perseus Proteomics: Change report (exemption share certificates, etc.)

Jun 21 14:16

Perseus Proteomics: Report on Corporate Governance, June 21, 2024.

Jun 21 09:46

Perseus Proteomics: Change report.

Jun 20 14:12

Perseus Proteomics: Extraordinary Report

Jun 20 13:40